Loading
Obesity, Morbid / 100 cm BP limb length / 150 cm BP limb length · Interventional Study
ClinicalTrials.gov · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned, ongoing interventional study evaluating weight loss and complications after variable biliopancreatic bypass surgery over 7 years, with concurrent measurement of molecular and metabolic biomarkers. No results are available in this registry record. The study is designed as an exploratory first step toward understanding mechanisms underlying heterogeneous weight loss surgery outcomes.
Interventional, Randomized, Parallel, Single masking, Basic Science purpose. Obesity, Morbid, Metabolic Syndrome, NASH - Nonalcoholic Steatohepatitis; age from 18 Years; to 80 Years; accepts healthy volunteers. Intervention: Standard BP limb length; Medium BP limb length; Long BP limb length. Compared with: Laparoscopic sleeve gastrectomy (surgical control) and non-surgical weight loss therapy (non-surgical control). n = 750. 1 site: United States.
This is a planned, ongoing interventional study evaluating weight loss and complications after variable biliopancreatic bypass surgery over 7 years, with concurrent measurement of molecular and metabolic biomarkers. No results are available in this registry record. The study is designed as an exploratory first step toward understanding mechanisms underlying heterogeneous weight loss surgery outcomes.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This study is not yet informative for clinical practice. When results are available, the mechanistic biomarker data (microbiome, enteroendocrine hormones, circulating miRNAs) may support precision-medicine approaches to weight loss surgery selection, but clinicians should await completed and published findings.
This is a planned interventional study with no results yet reported; it is designed to explore mechanisms of weight loss surgery through clinical and molecular endpoints over 7 years.
As stated by the source record.
Quoted from the source exactly as published.
This study is not yet informative for clinical practice. When results are available, the mechanistic biomarker data (microbiome, enteroendocrine hormones, circulating miRNAs) may support precision-medicine approaches to weight loss surgery selection, but clinicians should await completed and published findings.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04841057). This is a study registration, not published results. Lead sponsor: University of Missouri-Columbia. Recruitment status: ENROLLING_BY_INVITATION. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 750 participants (ESTIMATED). Conditions: Obesity, Morbid, Metabolic Syndrome, NASH - Nonalcoholic Steatohepatitis. Interventions: PROCEDURE: 50 cm BP limb length; PROCEDURE: 100 cm BP limb length; PROCEDURE: 150 cm BP limb length. Primary outcome measures: Weight loss after Variable Biliopancreatic Limb Length Bypass , 7 years; Complications after Variable Biliopancreatic Limb Length Bypass , 7 years. Brief summary: Variable outcomes after weight loss surgery are likely attributable to complex, poorly understood mechanisms. Due to the significant impact that morbid obesity has on a patient's health, successful management of obesity and its related comorbid medical conditions is important and thus necessitates continued improved therapies for treating obesity. Although the mechanisms of weight loss after surgical intervention are poorly understood, improved understanding of molecular and metabolic changes that occur after weight loss surgery may offer the ability to provide targeted precision therapy for patients with morbid obesity undergoing surgical therapy. In this proposal, the investigators will combine a clinical trial whereby modifications to the gold-standard for weight loss surgery, the gastric bypass, are evaluated while simultaneously measuring molecular and metabolic changes that occur in response to these weight loss procedures. Through creating variable lengths of bypass intestine after gastric bypass, the investigators will be able to determine the effect of malabsorption on clinical outcomes and mechanisms involved in weight loss after gastric bypass. The investigators will also use two control groups. One will be a surgical weight loss control group and consist of patients undergoing a laparoscopic sleeve gastrectomy, a non-intestinal bypass procedure. The other group will consist of patients having non-surgical weight loss therapy. To asses metabolic changes that occur in response to surgical weight therapy and specifically intestinal bypass and malabsorption, the investigators will examine changes in the gut microbiome and plasma gut enteroendocrine hormones. To evaluate molecular pathways that are impacted as a result of gastric bypass and malabsorption, the investigators will measure circulating microRNAs (miRNAs) in the blood. Measurement of miRNAs will provide data on an easily measurable molecular marker for each treatment group. This is a first step in translational exploration of mechanisms of weight loss after surgery by evaluating both clinical and molecular/metabolic outcomes and begin an explorative process towards creating an individualized approach to improving outcomes after weight loss surgery.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.